World's Best Scientists 2026 revealed!
Ahmad A. Tarhini

Ahmad A. Tarhini

D-Index & Metrics

Biology and Biochemistry

D-Index
63
Citations
16525
World Ranking
10093
National Ranking
4415

Overview

Ahmad A. Tarhini is affiliated with the Cleveland Clinic in the United States and has extensive research experience in the fields of Medicine and Biochemistry, Genetics, and Molecular Biology. Their work primarily focuses on oncology and related biomedical disciplines, with a considerable output in subfields such as Oncology, Molecular Biology, Immunology, Cancer Research, and Pulmonary and Respiratory Medicine.

The scientist's research topics encompass a diverse range of cancer-related themes, including:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Cutaneous Melanoma Detection and Management
  • Immunotherapy and Immune Responses
  • Melanoma and MAPK Pathways
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies

Ahmad A. Tarhini has contributed to multiple frequent publication venues, such as:

  • Journal of Clinical Oncology
  • Regular and Young Investigator Award Abstracts
  • Cancer Research
  • Annals of Oncology
  • Journal for ImmunoTherapy of Cancer

Among the co-authors who have frequently collaborated with Tarhini are:

  • Vernon K. Sondak
  • Nikhil I. Khushalani
  • Michelle L. Churchman
  • John M. Kirkwood
  • Aik Choon Tan

Significant papers authored or co-authored by Ahmad A. Tarhini include:

  • Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC), 2021, Nature Medicine
  • Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134, 2022, Journal of Clinical Oncology
  • Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204), 2021, Neuro-Oncology
  • Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial, 2022, The Lancet
  • DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial-ECOG-ACRIN EA6134, 2021, Journal of Clinical Oncology

Best Publications

  • Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

    Hussein A. Tawbi;Peter A. Forsyth;Alain Algazi;Omid Hamid

  • Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

    Celine Boutros;Ahmad Tarhini;Emilie Routier;Olivier Lambotte

  • Prognostic significance of autoimmunity during treatment of melanoma with interferon

    Michal T. Krauze;Ahmad Tarhini;Helen Gogas;John M. Kirkwood

  • Immunotherapy of Cancer in 2012

    John M. Kirkwood;Lisa H. Butterfield;Ahmad A. Tarhini;Hassane Zarour

  • Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab

    Ahmad A. Tarhini;Howard D Edington;Lisa H. Butterfield;Yan Lin

  • Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

    Ahmad A. Tarhini;Haris Zahoor;Yan Lin;Usha Malhotra

  • Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

    Alexander M. Menzies;Alexander M. Menzies;Rodabe N. Amaria;Elisa A. Rozeman;Alexander C. Huang

  • Next Generation of Immunotherapy for Melanoma

    John M. Kirkwood;Ahmad A. Tarhini;Monica C. Panelli;Stergios J. Moschos

  • Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management.

    Ahmad Tarhini

  • Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy

    John M. Kirkwood;Catherine Bender;Sanjiv Agarwala;Ahmad Tarhini

  • Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia

    Kenneth A. Foon;Michael Boyiadzis;Stephanie R. Land;Stanley Marks

  • PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen–Specific CD8+ T Cells Induced by Melanoma Vaccines

    Julien Fourcade;Zhaojun Sun;Ornella Pagliano;Joe Marc Chauvin

  • Future perspectives in melanoma research

    Paolo A. Ascierto;Sanjiv Agarwala;Gerardo Botti;Alessandra Cesano

  • The society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

    Howard L. Kaufman;John M. Kirkwood;F. Stephen Hodi;Sanjiv Agarwala

  • Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12

    Theofanis Floros;Ahmad A. Tarhini

  • Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study.

    L. Khoja;L. Khoja;E. G. Atenafu;S. Suciu;S. Leyvraz

  • Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors

    Ahmad Tarhini;Ernest Lo;David R. Minor

  • Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article.

    Donald N. Liew;Hideyuki Kano;Douglas Kondziolka;David Mathieu

  • Cutaneous melanoma: available therapy for metastatic disease.

    Ahmad A. Tarhini;Sanjiv S. Agarwala

  • Safety and efficacy of combination immunotherapy with interferon Alfa-2b and tremelimumab in patients with stage IV melanoma

    Ahmad A. Tarhini;John Cherian;Stergios J. Moschos;Hussein A. Tawbi

Frequent Co-Authors

John M. Kirkwood
John M. Kirkwood University of Pittsburgh
Lisa H. Butterfield
Lisa H. Butterfield University of California, San Francisco
Michael B. Atkins
Michael B. Atkins Georgetown University
Vernon K. Sondak
Vernon K. Sondak University of South Florida
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Kim Margolin
Kim Margolin City Of Hope National Medical Center
William E. Gooding
William E. Gooding University of Pittsburgh
F. Stephen Hodi
F. Stephen Hodi Harvard University
Omid Hamid
Omid Hamid Cedars-Sinai Medical Center
Antoni Ribas
Antoni Ribas University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re passionate about Biology and Biochemistry, a wide range of online degree paths and professional certifications can broaden your career options. For those interested in the healthcare side, psychiatric mental health nursing is in high demand. Completing the shortest pmhnp program can quickly lead to advanced nursing positions and expanded patient care opportunities.

Nutrition is also a fast-growing field in life sciences. Choosing a fastest nutrition degree online lets you quickly enter roles focused on public health, wellness, or clinical nutrition without lengthy campus commitments.

For those looking to combine science knowledge with leadership skills, a graduate degree in healthcare management may be a smart move. Considering the healthcare mba cost can help you find quality programs that fit your budget and career goals.

Certification also opens new doors. Understanding ccs certification options puts you on a path toward medical coding, data analysis, and informatics roles—key areas in today’s healthcare landscape.

Best Scientists Citing Ahmad A. Tarhini

Trending Scientists